Plunkett Research Online: Insmed Incorporated

INSMED INCORPORATED (INSM:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as .....



Insmed Incorporated
Ticker: INSM
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 908-977-9900
Fax:
Address: 700 US Highway 202/206
Bridgewater, NJ 08807 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Drugs-Metabolic & Endocrine Diseases
Pharmaceuticals
Clinical Testing
Drug Development
Oncology
Contacts Description
William Lewis CEO/Chairman of the Board/Director/President
Sara Bonstein CFO/Chief Accounting Officer
See More
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as .....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2021 2020 2019 2018 2017 2016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
ARIKAYCE
Brensocatib
Treprostinil Palmitil
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: